{"id":"gardasill-9-vaccine","safety":{"commonSideEffects":[{"rate":"60-70","effect":"Injection site pain"},{"rate":"20-30","effect":"Injection site swelling"},{"rate":"20-30","effect":"Injection site erythema"},{"rate":"10-15","effect":"Headache"},{"rate":"1-3","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains virus-like particles (VLPs) derived from the major capsid protein of nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). These VLPs are non-infectious but immunogenic, triggering both humoral and cellular immune responses. The induced antibodies neutralize HPV before it can establish infection in epithelial tissues, thereby preventing HPV-related malignancies and benign lesions.","oneSentence":"Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:13.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58"},{"name":"Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58"},{"name":"Prevention of oropharyngeal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58"},{"name":"Prevention of genital warts caused by HPV types 6, 11"},{"name":"Prevention of vulvar and vaginal cancers caused by HPV types 16, 18, 31, 33, 45, 52, 58"}]},"trialDetails":[{"nctId":"NCT03979014","phase":"PHASE3","title":"Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-11-01","conditions":"Neoplasia","enrollment":1099}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gardasill 9™ vaccine","genericName":"Gardasill 9™ vaccine","companyName":"Imperial College London","companyId":"imperial-college-london","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers. Used for Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of oropharyngeal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}